A/Prof Shom Goel
Principal Research Fellow
The Sir Peter MacCallum Department of Oncology
143 Scholarly works
12 Projects
HIGHLIGHTS
2026
Journal article
Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer
DOI: 10.1038/s41523-026-00913-42026
Journal article
CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors
DOI: 10.1016/j.ymthe.2026.03.0242026
Other
Data from A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer
DOI: 10.1158/1078-0432.c.78155712026
Journal article
Neoadjuvant atirmociclib plus letrozole versus letrozole alone in HR /HER2− breast cancer: Results from FourLight-2, a randomized phase 2 window of opportunity study.
DOI: 10.1200/jco.2026.44.16_suppl.5182025
Research grants (international)
FDP Reciprocal Data Transfer and Use Agreement With DFCI- Targeting Senescent Cells to Improve Outcomes for Breast Cancer Patients
2025
Research grants (ARC, NHMRC, MRFF)
Harnessing the Next Generation of Liquid Biopsy Assays for Clinical Translation in Breast Cancer
2022
Research grants (other domestic)
Understanding and Targeting Therapy-Induced Senescence in Cancer
RECENT SCHOLARLY WORKS
2026
Journal article
First disclosure of frontline treatment (1L tx) with the selective CDK4 inhibitor BGB-43395 in combination with letrozole for metastatic HR /HER2− breast cancer (BC): A phase 1 safety expansion.
DOI: 10.1200/jco.2026.44.16_suppl.10662026
Journal article
Single-cell transcriptomics reveals immune landscape dynamics in metastatic hormone receptor-positive breast cancer treated with abemaciclib and endocrine therapy.
DOI: 10.1158/1078-0432.CCR-25-09462026
Journal article
Abstract RF4-01: Central Nervous System Outcomes from the Phase III PATINA Trial (AFT-38)
DOI: 10.1158/1557-3265.sabcs25-rf4-012026
Conference Proceedings
Abstract GS3-06: Rb Functions as a Transcriptional Activator of ER Targets Following CDK4/6 Inhibition in Luminal Breast Cancer
DOI: 10.1158/1557-3265.sabcs25-gs3-062026
Journal article
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer
DOI: 10.1056/NEJMoa25112182025
Journal article
422TiP Randomized phase 2 trial of preoperative atirmociclib plus letrozole on Ki-67 tumor expression in HR /HER2− early breast cancer
DOI: 10.1016/j.annonc.2025.08.846
RECENT PROJECTS
2024
Research grants (international)
Enhancing the Benefits of CDK Inhibition in Breast Cancer
2022
Research grants (international)
Understanding and Targeting Therapy-Induced Senescence in Cancer